PMID- 8619211
OWN - NLM
STAT- MEDLINE
DCOM- 19960613
LR  - 20190914
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 119
IP  - 5
DP  - 1996 May
TI  - Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative 
      disorder after lung transplantation.
PG  - 544-51
AB  - BACKGROUND: Epstein-Barr virus (EBV)-associated posttransplantation 
      lymphoproliferative disorder (PTLD) is a serious complication of lung 
      transplantation. Besides immunosuppression the risk factors for PTLD development 
      are largely unknown. METHODS: The incidence of PTLD was ascertained in a lung 
      transplant population consisting of 45 patients. Nine patients (20%) experienced 
      PTLD. The clinical, histologic, and human leukocyte antigen (HLA) data were 
      collected on all patients. The incidence of EBV infection in lymphoid tissue 
      taken at the time of engraftment was studied by using EBV in situ hybridization. 
      RESULTS: All patients with PTLD had polymorphous lymphoproliferations, seven of 
      which were polymorphous B-cell hyperplasias and two of which were polymorphous 
      B-cell lymphomas. EBV was identified in all lesions. All patients with 
      polymorphous B-cell hyperplasias had clinically unsuspected disease, five of 
      which were identified at autopsy. The two polymorphous B-cell lymphoma lesions 
      were monoclonal and regressed with immunosuppression reduction. EBV in situ 
      hybridization on donor or recipient lymph nodes obtained at engraftment from the 
      45 transplant recipients showed no difference in the number of EBV positive cells 
      in patients with and without PTLD. Cyclosporine and PTLD and azathioprine dosages 
      and cyclosporine levels were similar between patients with and without PTLD. PTLD 
      was seen in patients with high cumulative doses of antilymphocyte globulin. 
      Analysis of HLA status showed a predominance of HLA A2 and DR7 in the donors of 
      the patients with PTLD, whereas donor HLA B7 was more common in patients without 
      PTLD> CONCLUSIONS: Detailed studies are necessary to further elucidate the risk 
      factors for PTLD development in the lung transplant population.
FAU - Montone, K T
AU  - Montone KT
AD  - Department of Pathology and Laboratory Medicine, Hospital of The University of 
      Pennsylvania, Philadelphia 19104, USA.
FAU - Litzky, L A
AU  - Litzky LA
FAU - Wurster, A
AU  - Wurster A
FAU - Kaiser, L
AU  - Kaiser L
FAU - Bavaria, J
AU  - Bavaria J
FAU - Kotloff, R
AU  - Kotloff R
FAU - Palevsky, H
AU  - Palevsky H
FAU - Pietra, G G
AU  - Pietra GG
FAU - Tomaszewski, J E
AU  - Tomaszewski JE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adult
MH  - Female
MH  - HLA Antigens/analysis
MH  - Herpesviridae Infections/*complications
MH  - *Herpesvirus 4, Human/genetics
MH  - Histocompatibility
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - In Situ Hybridization
MH  - Lung Transplantation/*adverse effects
MH  - Lymphoproliferative Disorders/pathology/*virology
MH  - Male
MH  - Middle Aged
MH  - RNA, Viral/analysis
MH  - Tissue Donors
MH  - Tumor Virus Infections/*complications
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - S0039-6060(96)80265-0 [pii]
AID - 10.1016/s0039-6060(96)80265-0 [doi]
PST - ppublish
SO  - Surgery. 1996 May;119(5):544-51. doi: 10.1016/s0039-6060(96)80265-0.